Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Editas Medicine Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
EDIT
Nasdaq
2836
https://www.editasmedicine.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Editas Medicine Inc
Why Editas Medicine Stock Is Soaring Today
- Sep 29th, 2023 3:21 pm
The Petri Dish: Ginkgo, Pfizer sign $331M deal; Leqembi OK'd in Japan
- Sep 28th, 2023 10:27 am
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
- Sep 25th, 2023 8:30 pm
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
- Sep 25th, 2023 1:00 pm
1 Gene Editing Stock to Buy Now, and 1 to Sell
- Sep 23rd, 2023 12:45 pm
Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock?
- Sep 8th, 2023 9:03 am
Ligand (LGND) Down 8.8% Since Last Earnings Report: Can It Rebound?
- Sep 7th, 2023 3:30 pm
Why Is Editas (EDIT) Down 4.3% Since Last Earnings Report?
- Sep 1st, 2023 3:31 pm
Editas Medicine Announces Upcoming Investor Events
- Aug 30th, 2023 1:00 pm
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
- Aug 28th, 2023 11:00 am
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
- Aug 23rd, 2023 12:25 pm
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Call Transcript
- Aug 4th, 2023 4:38 pm
Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus
- Aug 3rd, 2023 3:45 pm
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
- Aug 2nd, 2023 12:25 pm
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
- Aug 2nd, 2023 11:00 am
The past three years for Editas Medicine (NASDAQ:EDIT) investors has not been profitable
- Jul 31st, 2023 11:02 am
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
- Jul 27th, 2023 1:00 pm
The Petri Dish: Pfizer ends Syros collab; Editas hires 37-year Biogen vet
- Jul 27th, 2023 10:29 am
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
- Jul 26th, 2023 11:00 am
Scroll